[an error occurred while processing the directive]
RSS
Логотип
Баннер в шапке 1
Баннер в шапке 2

Roselectronics: Cardiorobot

Product
Developers: NPP Almaz
Last Release Date: 2024.02
Branches: Pharmaceuticals, Medicine, Healthcare
Technology: Robotics,  Robots Service

Content

Main article: Robots in Medicine

2024: Assembly of the first batch of prototypes "CardioRobot "

The first batch of prototypes of CardioRobot has been collected. Such information was shared on February 2, 2024 by representatives of the Roselectronics holding.

According to Mikhail Apin, Director General of the Almaz NPP, the first stage of preclinical testing of devices at the Almazov National Medical Research Center was also carried out. Together with partners, a device assembly line and a test line are equipped. Clinical trials and marketing authorization are planned.

File:Aquote1.png
"In 2025, we plan to launch mass production and deliver the first 800 robots to customers," added the head of the Almaz NPP.
File:Aquote2.png

The development of CardioRobots with the support of the Ministry of Industry and Trade of Russia is carried out by NPP Almaz (part of Roselectronics) together with Medical Robotics LLC.

2023: Presentation of the finished device, production start date

The first Russian robotic complex for indirect heart massage has been officially presented. We are talking about a device called CardioRobot, which, with the support of the Ministry of Industry and Trade of the Russian Federation, has developed the Almaz NPP of the Roselectronics holding.

According to the press service Rostec of "" (Roselectronics is part of this state corporation), CardioRobot is an automated device for indirect heart massage during cardiopulmonary resuscitation. Thanks to the patient's vital activity sensors, the device regulates the pressure and depth of compression. The device can be used in intensive care and intensive care units cars , emergency medical services, transplant units.

The first Russian robotic complex for indirect heart massage has been developed

According to the developers, unlike a person who can qualitatively perform indirect heart massage for no more than 2-3 minutes, the device is capable of working on battery power for up to 45 minutes. The solution increases the chances of patients in critical condition to survive and reduces the burden on medical personnel. The device is equipped with a non-invasive blood pressure cuff and a SpO2 sensor that measures the level of blood oxygen saturation.

As the general director of NPP Almaz Mikhail Apin said, by July 12, 2023, the company received 1,500 confirmed applications for the supply of CardioRobots. By this time, a sample product has been created, the technical characteristics of which meet international requirements, he said. The launch of serial production of the device is scheduled for 2025.

File:Aquote1.png
According to our calculations, about 9 thousand devices for cardiopulmonary resuscitation are required to equip hospitals, as well as ambulances. There is currently no such equipment of domestic production on the market, this equipment is supplied from abroad, - added Apin.[1]
File:Aquote2.png

2021: Creation of "Cardiorobots"

In December 2021, it became known that NPP Almaz (part of the Roselectronics holding of the Rostec state corporation) was engaged in the development of Cardiorobots, and then will produce them. We are talking about automated devices for indirect heart massage during resuscitation.

According to the press service of Rostec, Cardiorobot will ensure continuous chest compressions to maintain blood circulation in patients with sudden cardiac arrest. The battery life of the device will be up to 45 minutes, while a person is able to qualitatively perform indirect heart massage for no more than 2-3 minutes. Thanks to the patient's life sensors, the operation of the device will be fully automated: the "cardiorobot" will be able to turn on during cardiac arrest, regulate pressure and compression depth.

"Cardiorobot" will provide continuous chest compressions to maintain circulation in patients with sudden cardiac arrest.

The equipment will be used in intensive care units cars , emergency medical care, transplant units.

The total cost of the project will be 329 million, rubles financing is carried out at the expense of own funds of NPP Almaz and subsidies under the agreement with. Ministry of Industry and Trade Russia

General Director of NPP Almaz Mikhail Apin listed three main tasks that the company sets within the framework of this project:

  • Create a device with a high level of automation
  • develop a product with such performance characteristics that will fully satisfy resuscitators. To do this, the developers consult with employees of the Department of Emergency Anesthesiological and Resuscitation Care of Saratov State Medical University;
  • offer customers a lower price for products than foreign counterparts.

According to Apin, there are no such devices of domestic production on the market by mid-December 2021.[2]

Notes